Lin Shen


Country: China


  1. Gao J, Lu M, Yu J, Li Y, Shen L. Thymidine Phosphorylase/?-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer. 2011;11:177 pubmed publisher
    ..Further prospective evaluation in large samples should be performed to confirm these preliminary findings. ..
  2. request reprint
    Zhang J, Wang X, Shen L. [Impacts of microsatellite status, RAS and BRAF mutation on postoperative follow-up strategy in stage II( and III( colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2018;21:716-720 pubmed
    ..Combination of TNM staging and molecular markers for more stratified management and establishment of individualized follow-up system are clinically meaningful in the future. ..
  3. request reprint
    Li Y, Gao J, Tian Y, Li J, Shen L. [Mutation profiles of c-kit/PDGFRα and its associations with clinicopathological characteristics in Chinese gastrointestinal stromal tumors: analysis of 827 cases]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18:332-7 pubmed
    ..05). GISTs are featured by frequent gene mutations, many mutation types, and specificity for mutations in same exons or different exons. ..
  4. Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016;19:234-44 pubmed publisher
    ..The mDCF regimen achieved efficacy comparable to that of DCF but with fewer toxicities, which is appropriate for the Chinese population. ..
  5. request reprint
    Zhou J, Deng W, Gao J, Yuan J, Li Y, Shen L. [Association between ABCB1 G2677T/A polymorphisms and chemosensitivity of paclitaxel in advanced gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18:123-6 pubmed
    ..05). ABCB1 G2677T/A polymorphisms are associated with chemosensitivity of paclitaxel in gastric cancer. ..
  6. request reprint
    Wang X, Shen L. [Current status of the study on hereditary diffuse gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18:295-7 pubmed
    ..In China, the studies on hereditary diffuse gastric cancer are sparse. We hope this article will bring more awareness and attention of this peculiar disease to Chinese physicians. ..
  7. request reprint
    Tian Y, Gao J, Li J, Li Y, Qi C, Shen L. [Analysis of clinicopathological characteristics in 180 patients with wild type gastrointestinal stromal tumors]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18:342-5 pubmed
  8. Peng Z, Li Z, Gao J, Lu M, Gong J, Tang E, et al. Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. 2015;14:2634-41 pubmed publisher
    ..In 96 evaluable patients, p-MET positivity was significantly associated with MET amplification (P < 0.001). Further evaluation in larger and independent sample sets is warranted to confirm our findings. ..
  9. request reprint
    Wang X, Wei Q, Shen L. [Controversy of primary tumor resection for stage IV colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2016;19:105-8 pubmed
    ..This article will review the role of PTR in incurable stage IV CRC, including the advantages and risks, with emphasis on identifying patients who may benefit from this palliative intervention. ..

More Information


  1. Wang Z, Wang X, Yuan J, Zhang X, Zhou J, Lu M, et al. Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study. Clin Colorectal Cancer. 2018;17:e233-e255 pubmed publisher
    ..Local treatments of LM may confer a survival benefit in the palliative setting. First-line single-agent fluoropyrimidine may be used in patients with good prognosis. ..
  2. Xu R, Shen L, Wang K, Wu G, Shi C, Ding K, et al. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chin J Cancer. 2017;36:97 pubmed publisher
    ..Famitinib prolonged PFS in refractory mCRC patients with acceptable tolerability. Trial registration This study was registered on (NCT01762293) and was orally presented in the 2015 ASCO-Gastrointestinal Symposium. ..
  3. request reprint
    Zou J, Gao J, Shen L. [Transformation of patient-derived tumor xenografts into lymphomas: characteristics, influence factors and precautions]. Zhonghua Wei Chang Wai Ke Za Zhi. 2016;19:833-7 pubmed
    ..Therefore, selective xenograft by the detection of EBV infection and inflammation infiltration in primary tumors may be effective methods to prevent lymphomagenesis. ..
  4. Li Z, Lai Y, Sun L, Zhang X, Liu R, Feng G, et al. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol. 2016;55:182-9 pubmed publisher
    ..011). These results suggest that massive lymphocyte infiltration and the diffuse/mixed type histology of GC should be taken into consideration to select the appropriate patients for PD-L1 inhibitory treatment in the future. ..
  5. Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. 2016;16:68 pubmed publisher
    ..6%), neutropenia (13.7%), anemia (5.9 %) and leucopenia (3.9%). The addition of trastuzumab to oxaliplatin/capecitabine was well tolerated and the results demonstrated encouraging efficacy. NCT01364493. ..
  6. Xu R, Shen L, Li J, Xu J, Bi F, Ba Y, et al. Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chin J Cancer. 2016;35:13 pubmed publisher
  7. Zhu Y, Tian T, Zou J, Wang Q, Li Z, Li Y, et al. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. BMC Cancer. 2015;15:894 pubmed publisher
    ..These important findings can be utilized to facilitate the design of future clinical trials. ..
  8. Xu Y, Peng Z, Li Z, Lu M, Gao J, Li Y, et al. Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma. BMC Cancer. 2015;15:6 pubmed publisher
    ..007). c-Met may be an independent prognostic factor in advanced ESCC. The overexpression of c-Met may predict a worse efficacy of anti-EGFR therapy. ..
  9. request reprint
    Zhang P, Shen L. [Implementation of multidisciplinary team in the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasm]. Zhonghua Wei Chang Wai Ke Za Zhi. 2016;19:1205-1210 pubmed
    ..This paper investigates the significance and management in the implementation of MDT model in the diagnosis and treatment of GEP-NEN, based on the experience of MDT operation in our center. ..
  10. Wang X, Wei Q, Gao J, Li J, Li J, Gong J, et al. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Chin J Cancer. 2017;36:81 pubmed publisher
    ..Compared with standard treatment regimens, the FOLFOXIRI regimen had acceptable and manageable toxicities and favorable efficacy on patients with BRAF-mutated mCRC. ..
  11. request reprint
    Li Y, Peng Z, Zhang X, Gong J, Shen L. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2017;20:1293-1299 pubmed
    ..The acquirement of elevated HER2 ECD level can also be found in histologically HER2 negative patients, which may be correlated to the corresponding variation of CTC number. ..
  12. Wang H, Li B, Liu Z, Gong J, Shao L, Ren J, et al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer. 2018;88:92-100 pubmed publisher
    ..ctDNA for HER2 analysis was strongly recommended to serve as a surrogate to screen trastuzumab-suitable population and monitor trastuzumab efficacy. ..